Clinical Hematology International

Volume 1, Issue 4, December 2019

1. Immune Thrombocytopenia: Are We Stuck in the Mud or Is There Light at the End of the Tunnel?

James Bussel, Oriana Miltiadous
Pages: 173 - 179
The differences in diagnosis and management between immune thrombocytopenia (ITP) and leukemia are striking. Leukemia diagnosis and management have evolved substantially over the past 30 years and are now relatively precise. The tendency for leukemic cells to be the overwhelming majority of circulating...
Review Article

2. Managing Endocrine Disorders in Adults After Hematopoietic Stem Cell Transplantation

Juliana Matthews, Dwight Eplin, Bipin Savani, Barbara Gisella Carranza Leon, Leslee Matheny
Pages: 180 - 188
Hematopoietic stem cell transplantation (HSCT) has become a potentially curative therapy for an increasing number of malignant and non-malignant conditions. As survival rates continue to improve, the focus of patient care has shifted from managing not only immediate but also long-term complications....
Review Article

3. Moving Toward Continuous Therapy in Multiple Myeloma

Francesca Bonello, Giusy Cetani, Luca Bertamini, Francesca Gay, Alessandra Larocca
Pages: 189 - 200
The introduction of novel agents, characterized by favorable toxicity profiles and higher manageability compared to conventional drugs employed in the past, has considerably changed the treatment paradigm for multiple myeloma. Continuous therapy currently represents the standard approach for myeloma...
Research Article

4. Elevated Galectin-3 Plasma Concentrations in Recipients of Allogeneic Hematopoietic Cell Transplantation

Zachariah DeFilipp, Nalu Navarro-Alvarez, Shuli Li, Alec R. Andrews, Ariel Johnson, Yi-Bin Chen, Vincent T. Ho, Jerome Ritz, Thomas R. Spitzer, Christene A. Huang
Pages: 201 - 204
Galectin-3 is a beta-galactoside-binding lectin with an established association to inflammatory and fibrotic conditions. We investigated galectin-3 levels in 68 recipients of allogeneic hematopoietic cell transplantation (HCT) to look for associations with chronic graft-versus-host disease (cGVHD). Plasma...
Research Article

5. Induction Therapy with Novel Agents and Autologous Stem Cell Transplant Overcomes the Adverse Impact of Renal Impairment in Multiple Myeloma

Lalit Kumar, Santosh Kumar Chellapuram, Ramavat Dev, Ankur Varshneya, Satyajit Pawar, Aparna Sharma, Anjali Mookerjee, Ranjit Kumar Sahoo, Prabhat Singh Malik, Atul Sharma, Ritu Gupta, Omdutta Sharma, Ahitagni Biswas, Rakesh Kumar, Sanjay Thulkar, Sauumyaranjan Mallick
Pages: 205 - 219
We investigated the impact of renal impairment (RI) on the outcome in multiple myeloma (MM) patients following induction and autologous stem cell transplantation (ASCT). Among 349 patients who received a first ASCT for MM, 86 (24.6%) had RI at diagnosis, defined as estimation of glomerular filtration...
Research Article

6. The Clinical Course of Multiple Myeloma in the Era of Novel Agents: A Retrospective, Single-Center, Real-World Study

Agoston Gyula Szabo, Katrine Fladeland Iversen, Sören Möller, Torben Plesner
Pages: 220 - 228
In this retrospective study we reviewed the clinical course of every patient with multiple myeloma treated from 2006 to 2016 at Vejle Hospital: 303 patients with a median age of 69 years at diagnosis received a median of four (range 1–18) lines of therapy; 149 in a 2006–2010 cohort and 154 in a 2011–2016...
Research Article

7. Use of Biosimilar Granulocyte Colony-Stimulating Factor for Mobilization in Autologous and Allogeneic Hematopoietic Stem Cell Transplantation

Dwight D. Eplin, Anna D. Jackson, Austin M. Smith, Brent Salvig, Wichai Chinratanalab, Bipin N. Savani
Pages: 229 - 233
The biologic medication filgrastim is approved by the Food and Drug Administration (FDA) to mobilize hematopoietic progenitor cells (HPCs) for collection by leukapheresis for autologous hematopoietic stem cell transplant (HSCT). The FDA-approved biologic tbo-filgrastim is currently used off-label for...